Abstract: Disclosed is a fusion protein for ?-Melanocyte stimulating hormone, the fusion protein containing a protein transduction domain (PTD), a human serum albumin (HSA) and an ?-Melanocyte stimulating hormone (?-MSH). Also disclosed are a method for preparing the fusion protein and a use thereof for inhibiting or treating central nervous system inflammations.

Abstract: An automatic cleaning method and a cleaning bed for a patient of gatism are provided. The cleaning bed includes a bed body, a bed plate is arranged on the bed body and is provided with a through groove therein, a bed bottom plate is arranged on a lower part of the bed body, a lifting mechanism is arranged on the bed bottom plate and is provided with a soft cushion thereon, a fabric bracket is arranged under the bed plate and is provided with a material roller thereon, a pressing roller bracket is arranged under the bed plate and at one side close to the fabric bracket and is provided with provided with a first pressing roller and a second pressing roller.

Abstract: The present subject matter relates to compounds that have aggregation-induced emission (AIE) characteristics and are capable of generating Raman signals in the Raman cell-silent region (1800 cm?1-2800 cm?1). The compounds can be used in dual-mode cell imaging by fluorescence and Raman microscopes.

Abstract: Provided is a display module, including: a shell; a display panel, wherein the display panel is disposed in the shell and is connected to the shell; a first light emitting component, wherein the first light emitting component is connected to the display panel and is configured to emit light of a target wavelength; and a fingerprint recognition sensor, wherein the fingerprint recognition sensor is disposed between the shell and the display panel and is fixedly connected to the shell; an orthographic projection of the fingerprint recognition sensor onto the display panel and an orthographic projection of the first light emitting component onto the display panel do not overlap; and the fingerprint recognition sensor is configured to recognize a fingerprint based on received light of the target wavelength reflected by an obstacle.

Abstract: This application provides a packaging structure, including an antenna in package and a radio frequency chip that are packaged together, where the antenna in package is fastened on the radio frequency chip. The antenna in package includes a radiator and at least two feeding parts, the at least two feeding parts are electrically connected to the radio frequency chip, the radio frequency chip is configured to receive or transmit a radio frequency signal, and at least one of the at least two feeding parts provides differential feeding for the radiator. This application further provides a network device and a terminal device, to reduce an antenna size and make the antenna easier to mount.

Abstract: Provided is a buccal micro-effervescent tablet and preparation method thereof. The buccal micro-effervescent tablet comprises a nutrient, a sugar alcohol, an acid source, an alkali source, magnesium stearate, an essence and a sweetening agent, wherein the sugar alcohol is lactose, maltitol, sorbitol, isomaltitol, mannitol, erythritol or any combination thereof; the sweetening agent is sucralose, aspartame, stevioside, fructose, granulated sugar, mogroside or any combination thereof. The micro-effervescent tablet may cause micro effervescence reaction under the action of saliva in mouth.

Abstract: A tofu press includes: an open container, a foldable plate, a pressing plate, a spring assembly, and an end cover, where the foldable plate is configured to be placed at a bottom of the open container, the foldable plate includes a bottom plate and lateral plates disposed at two sides of the bottom plate, the lateral plates are perpendicular to and connected to the bottom plate, the pressing plate is configured to cover and press a top of the bottom plate, a bottom end of the spring assembly is configured to press the pressing plate, and the spring assembly is fixedly connected to the end cover; and the pressing plate, the lateral plates, the bottom plate, and two faces of the open container form a compression operating area. The tofu press ensures uniform pressing at the time of pressing a food material to dehydrate.

Abstract: The disclosure relates to a sucrose phosphorylase mutant with improved enzyme activity, and construction method thereof and use thereof, and belongs to the technical field of genetic engineering. The amino acid sequence of the mutant of the disclosure is as shown in SEQ ID NO: 1. The mutant of the disclosure is based on sucrose phosphorylase derived from Leuconostoc mesenteroides, and subjected to site-directed mutagenesis to improve the enzyme activity of sucrose phosphorylase. The mutant is expressed in Corynebacterium glutamicum and used as a whole cell catalyst to produce 2-O-?-D-glycerol glucoside. At a 5 L fermentation tank level, a large quantity of 2-O-?-D-glycerol glucoside can be produced efficiently in a short time, which is conducive to expanding the prospect of industrial application of sucrose phosphorylase for the production of 2-O-?-D-glycerol glucoside and realizing its large-scale industrial application.

Abstract: The present disclosure provides a flexible suit and a flexible system for rehabilitation training of a human leg. The flexible suit includes a first hip joint motion assembly, a first knee joint motion assembly and a first ankle joint motion assembly, a first end of the first knee joint motion assembly is connected with the first hip joint motion assembly, a second end of the first knee joint motion assembly is connected with the first ankle joint motion assembly, the first hip joint motion assembly, the first knee joint motion assembly, and the first ankle joint motion assembly each includes a flexible mechanism, and at least one of a group consisting of the first hip joint motion assembly, the first knee joint motion assembly, and the first ankle joint motion assembly is configured to operate under gas drive.

Abstract: The disclosure discloses 17?-hydroxysteroid dehydrogenase mutants and application thereof, and belongs to the technical field of biology. The disclosure provides 17?-hydroxysteroid dehydrogenase mutants V107A, T155N, H164Y and V107A/T155N/H164Y with high specific enzyme activities, and the specific enzyme activities of the 17?-hydroxysteroid dehydrogenase mutants V107A, T155N, H164Y and V107A/T155N/H164Y are as high as 1.85, 1.93, 2.06 and 5.15 U/mg, respectively, which are 1.11, 1.16, 1.24 and 3.10 times larger than that of wild-type 17?-hydroxysteroid dehydrogenase (1.66 U/mg).

Abstract: Provided are hybrid tRNA/pre-miRNA molecules, e.g., comprising a single tRNA and one, two or more pre-miRNA molecules, useful for the production and therapeutic delivery of an inserted RNA sequence, e.g., one or more miRNAs. Also provided are liposomes and nanoparticles that include the hybrid tRNA/pre-miRNA molecules. Methods of treating cancer by administration of the hybrid tRNA/pre-miRNA molecules are also provided.

Abstract: The present invention relates to N-aromatic amide compounds with formula (I) and/or (II) and preparation methods therefor, pharmaceutical compositions and pharmaceutical formulations containing the compounds with formula (I) and/or (II), and use of the compounds with formula (I) and/or (II) in preparing a medicament for the treatment of diseases related to androgens. The definitions of R1, R2, R3, R4, R5, R6, W1, W2, W3, W4 and W5 in the formula are the same as those in the description. The compounds with the formula (I) and/or (II) are capable of binding to the androgen receptors and have activity for anti-androgen and degrading androgen receptor. The compounds can be used alone or as compositions for the treatment of various androgen-related diseases such as prostate cancer, prostate hyperplasia, breast cancer, bladder cancer, ovarian cancer and the like, and also for the treatment of acne, hirsutism, psilosis and other diseases.

Abstract: The present invention discloses a method for producing a 1,2-amino alcohol compound by utilizing whole-cell transformation, and belongs to the technical field of gene engineering and microorganism engineering. According to the present invention, engineered Escherichia coli co-expresses epoxide hydrolase, alcohol dehydrogenase, ?-transaminase and glutamate dehydrogenase, is capable of realizing whole-cell catalysis of an epoxide in one step to synthesize a 1,2-amino alcohol compound, and meanwhile, can realize regeneration of coenzyme NADP+ and an amino doner L-Glu; alcohol dehydrogenase expressed by the engineered Escherichia coli is RBS optimized alcohol dehydrogenase, and such RBS optimization can control the expression quantity of alcohol dehydrogenase, so that the catalysis rate of alcohol dehydrogenase and transaminase can achieve an optimum ratio, to eliminate influence caused by a rate-limiting step in a catalyzing course.

Abstract: The present subject matter relates to compounds that have aggregation-induced emission (AIE) characteristics and are capable of generating Raman signals in the Raman cell-silent region (1800 cm?1-2800 cm?1).

Abstract: The present disclosure discloses a thermophilic L-asparaginase mutant and screening and fermentation methods thereof, and belongs to the field of gene engineering, enzyme engineering and fermentation engineering. In Bacillus subtilis 168, a Pyrococcus yayanosii CH1-derived L-asparaginase encoding gene is used as a template, and a mutation library is constructed by an error-prone PCR (epPCR) technology. A mutant strain with improved specific enzyme activity is screened through a high-flux screening method of synchronous cell disruption and enzyme activity measurement. Mutated residues included in a positive mutant are analyzed to construct a composite mutant strain S17G/A90S/R156S/K272A with improved specific enzyme activity and specific enzyme activity of 3108 U/mg. An expression quantity of the composite mutant strain in the Bacillus subtilis 168 is increased through measures of a strong promoter P43 and RBS optimization.

Abstract: The present disclosure discloses a method for producing 9?-hydroxy androstane-4-alkene-3,17-diketone by enzymatic conversion, and belongs to the fields of gene engineering and enzyme engineering. According to the present disclosure, oxidation subunit KshA, reduction subunit KshB and unknown active subunit KshC of 3-ketosteroid-9?-hydroxylase sourcing from Mycobacterium sp. Strain VKM Ac-1817D are successfully expressed in E. coli BL21, and KshC is identified as an oxidation subunit, the enzyme activity of which is far higher than that of KshA. BL21/pET-28a(+)-fdh constructed in the laboratory is used for expressing formate dehydrogenase (FDH), and by using crude enzyme liquid of KSH (KshB+KshC) and FDH engineering bacteria as a biocatalyst and a steroidal compound (AD) as a substrate, optimum reaction temperature is determined as 30° C. and optimum pH is determined as 7.0. In optimum conditions, AD is converted to produce a product 9-OH-AD, and within 20 hours, the output of 9-OH-AD is 4.

Abstract: The disclosure relates to a sucrose phosphorylase mutant with improved enzyme activity, and construction method thereof and use thereof, and belongs to the technical field of genetic engineering. The amino acid sequence of the mutant of the disclosure is as shown in SEQ ID NO: 1. The mutant of the disclosure is based on sucrose phosphorylase derived from Leuconostoc mesenteroides, and subjected to site-directed mutagenesis to improve the enzyme activity of sucrose phosphorylase. The mutant is expressed in Corynebacterium glutamicum and used as a whole cell catalyst to produce 2-O-?-D-glycerol glucoside. At a 5L fermentation tank level, a large quantity of 2-O-?-D-glycerol glucoside can be produced efficiently in a short time, which is conducive to expanding the prospect of industrial application of sucrose phosphorylase for the production of 2-O-?-D-glycerol glucoside and realizing its large-scale industrial application.

Abstract: Provided are hybrid tRNA/pre-microRNA and tRNA molecules and their use in methods of preventing and treating hepatocellular carcinoma (HCC). In some embodiments, provided are polynucleotides that include a tRNA operably linked to one or more pre-microRNA (pre-miRNA), where the tRNA and/or pre-miRNA are operably linked to one or more inserted RNA molecules that inhibit the growth or proliferation of a hepatocellular carcinoma (HCC) cell.

Abstract: The disclosure discloses 17?-hydroxysteroid dehydrogenase mutants and application thereof, and belongs to the technical field of biology. The disclosure provides 17?-hydroxysteroid dehydrogenase mutants V107A, T155N, H164Y and V107A/T155N/H164Y with high specific enzyme activities, and the specific enzyme activities of the 17?-hydroxysteroid dehydrogenase mutants V107A, T155N, H164Y and V107A/T155N/H164Y are as high as 1.85, 1.93, 2.06 and 5.15 U/mg, respectively, which are 1.11, 1.16, 1.24 and 3.10 times larger than that of wild-type 17?-hydroxysteroid dehydrogenase (1.66 U/mg).

Abstract: The present subject matter relates to ATE luminogens for visualization and treatment of cancer, particularly AIE luminogenic probes for cancer cell visualization and discrimination, lysosome-targeting AIEgens for imaging and autophagy visualization, highly fluorescent AIE-active theranostic agents for monitoring drug distribution and having anti-tumor activity to specific cancer cells, probes comprising AIE luminogens for cancer cell imaging and staining, AIE luminogens having clusteroluminogenic features and applications thereof, and methods of preparing thereof.